Share Name Share Symbol Market Type Share ISIN Share Description
Proteome LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 4.875p 4.75p 5.00p 5.10p 5.00p 5.10p 186,628 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -2.9 -1.0 - 14.36

Proteome Sciences PLC Launch of new website

19/12/2016 7:00am

RNS Non-Regulatory


TIDMPRM

Proteome Sciences PLC

19 December 2016

Proteome Sciences plc

Launch of new website

Proteome Sciences plc (AIM:PRM) (the "Company") is pleased to announce the launch of its newly designed corporate website, as anticipated in the Company's interim results statement of 14 September 2016. The website may be found at Proteome's existing web domain of www.proteomics.com.

Corporate information published pursuant to Rule 26 of the AIM Rules for Companies remains available from this website.

For further information:

 
 Proteome Sciences plc 
 Jeremy Haigh, Chief Executive 
  Officer 
 Ian Pike, Chief Scientific           Tel: +44 (0)1932 865065 
  Officer 
 Geoff Ellis, Chief Financial 
  Officer 
 
 finnCap Ltd (Nominated Adviser 
  & Broker)                             Tel : +44 (0)20 7220 
  Geoff Nash/James Thompson             0500 
  Tony Quirke (Broking) 
 
 IFC Advisory (Public Relations)      Tel : +44 (0) 203 053 
  Tim Metcalfe/Graham Herring/Miles    8671 
  Nolan 
 

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGGCGPUPQGMM

(END) Dow Jones Newswires

December 19, 2016 02:00 ET (07:00 GMT)

1 Year Proteome Chart

1 Year Proteome Chart

1 Month Proteome Chart

1 Month Proteome Chart
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:gb D:20170524 23:30:11